2013 Fiscal Year Final Research Report

Investigation of relationship between the pharmacokinetics of and clinical responses to prochlorperazine in patients receiving opioids

Research Project

Project/Area Number	23790181
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Medical pharmacy
Research Institution	Hamamatsu University School of Medicine
Principal Investigator	NAITO Takafumi 浜松医科大学, 医学部附属病院, 副薬剤部長 (80422749)
Research Collaborator	TASHIRO Masaki 浜松医科大学, 医学部附属病院, 薬剤師
Project Period (FY)	2011 – 2013
Keywords	プロクロルペラジン / オピオイド / 薬物動態 / 有害作用 / ドパミンD2受容体 / オピオイドμ1受容体 / 遺伝子多型 / 緩和医療
Research Abstract	Prochlorperazine has a high potency antiemetic effect based on inhibiting dopamine D2 receptor and is commonly used for the treatment of opioid-induced nausea and vomiting in cancer patients. Clinical responses to prochlorperazine vary in patients receiving opioids. Opioids bind to opioid receptor mu1 on the hypothalamus and subsequently cause the blockade of dopaminergic pathways. This study evaluated the interindividual variation in pharmacokinetics of and clinical responses to prochlorperazine based on non-genetic and genetic factors in patients receiving opioids.